Sugi Predict

Sugi Predict / Targets / FER

FER

Tyrosine-protein kinase Fer · P16591 · FER on Sugi Atlas →

78,311 patent compounds predicted against FER, 62,994 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL24615 SCHEMBL24615 0.51 8/20
SCHEMBL232042 SCHEMBL232042 1.00 3/20
Ucn-01 Ucn-01 (SCHEMBL259162) 1.00 3/20
SCHEMBL264158 SCHEMBL264158 0.79 3/20
SCHEMBL299518 SCHEMBL299518 0.76 3/20
SCHEMBL213187 SCHEMBL213187 0.43 3/20
Sunitinib Sunitinib (SCHEMBL8081) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL8082) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL93829) 1.00 2/20
Crizotinib Crizotinib (SCHEMBL94020) 1.00 2/20
SCHEMBL201744 SCHEMBL201744 1.00 2/20
SCHEMBL201745 SCHEMBL201745 1.00 2/20
Tae-684 Tae-684 (SCHEMBL282775) 1.00 2/20
Sunitinib Sunitinib (SCHEMBL18648) 0.92 2/20
Sunitinib Sunitinib (SCHEMBL55459) 0.84 2/20
SCHEMBL202187 SCHEMBL202187 0.81 2/20
SCHEMBL167615 SCHEMBL167615 0.80 2/20
SCHEMBL232936 SCHEMBL232936 0.79 2/20
SCHEMBL143584 SCHEMBL143584 0.78 2/20
SCHEMBL143543 SCHEMBL143543 0.77 2/20

Clinical trials — most relevant to FER by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer PHASE3RECRUITING
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme PHASE2UNKNOWN
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer PHASE1/PHASE2COMPLETED
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer PHASE2COMPLETED
MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy PHASE1/PHASE2COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer PHASE2COMPLETED
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC) PHASE2RECRUITING
A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer PHASE2WITHDRAWN
Carboplatin Taxol Avastin in Ovarian Cancer (OVCA) PHASE2COMPLETED
Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer PHASE2UNKNOWN
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma PHASE2COMPLETED
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia PHASE1RECRUITING
Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor PHASE1RECRUITING
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC PHASE1COMPLETED
The Development of Human Immunologic Assays Specific to Folate Receptor Antigen nanUNKNOWN
[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib nanCOMPLETED
Ruxolitinib in Patients With Myelofibrosis nanUNKNOWN
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
XL999 Administered Intravenously to a Subject With Advanced Malignancies nanNO_LONGER_AVAILABLE
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
FLT3-ITD Gene Mutation and CD135 Expression in Acute Myeloid Leukemia. nanUNKNOWN
Spanish Study for Molecular Characterization of Thyroid Carcinoma nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a FER binder may also engage these)

ProteinNameSimilarity
P09760 — 1.000 P09760 →
Q9TTY2 — 1.000 Q9TTY2 →
P70451 — 0.999 P70451 →
Q9R0C8 — 0.986 Q9R0C8 →
Q07139 — 0.983 Q07139 →
Q9H8V3 — 0.981 Q9H8V3 →
Q62245 — 0.977 Q62245 →
Q9DDA9 — 0.977 Q9DDA9 →
P52735 — 0.977 P52735 →
Q4V920 — 0.976 Q4V920 →
SNX9 Sorting nexin-9 0.976 landscape →
P53666 — 0.974 P53666 →
Q9UKW4 — 0.974 Q9UKW4 →
Q08DN7 — 0.973 Q08DN7 →
A0A3Q1LSX9 — 0.973 A0A3Q1LSX9 →
Q9NXL2 — 0.973 Q9NXL2 →
Q00944 — 0.973 Q00944 →
Q91821 — 0.973 Q91821 →
Q5R411 — 0.972 Q5R411 →
B2RQE8 — 0.972 B2RQE8 →
VAV1 Proto-oncogene vav 0.972 landscape →
Q9BY11 — 0.971 Q9BY11 →
SOS1 Son of sevenless homolog 1 0.971 landscape →
Q91VH2 — 0.971 Q91VH2 →
Q6GNV5 — 0.971 Q6GNV5 →
Q9WVE8 — 0.971 Q9WVE8 →
A7MBL8 — 0.971 A7MBL8 →
PTK2 Focal adhesion kinase 1 0.970 landscape →
P25911 — 0.970 P25911 →
Q5M7Y0 — 0.970 Q5M7Y0 →